Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer Guidelines Pocket Guide - Guideline Central

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

American Society of Clinical OncologyPublished: April 19, 2022
  • Pages:14
  • Format:Spiral Bound
  • Dimensions:4.25" x 7.25"
$9.95
A PDF version of this Pocket Guide is also available!
$9.95
  • Key Points
  • Recommendations for the use of biomarkers
    • For patients who present with a hormone receptor positive, HER2 not overexpressed, axillary node negative early breast cancer
    • Early-Stage Invasive Breast Cancer with Known ER/PgR and HER2 Status
    • Additional Biomarkers to Guide Specific Drug/Regimen Choice
  • Algorithm
    • Algorithm on Biomarkers to Guide Decisions on Adjuvant Endocrine and Chemotherapy
  • Tables
    • Breast Cancer Biomarkers to Guide Adjuvant Therapy Newly Diagnosed
    • Classification of Patients According to Clinical Risk Assessment by the Modified Version of Adjuvant!Online as Reported by Cardoso et al, 2016
Also Found In

ASCO Guidelines Bundle

$935.95
Related Products
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.